Kerstin Kutsche
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kerstin Kutsche has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
Andreas Gal
4 shared publicationsGeorg Rosenberger
Institut für Humangenetik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
4 shared publicationsA. Gal
2 shared publicationsGabriele Gillessen-Kaesbach
Institute of Human Genetics, University of Lübeck, Lübeck
2 shared publicationsPeter Meinecke
2 shared publicationsUlrike Orth
2 shared publications
Latest Publications
- 24 February 2009
- Published by Hindawi Limited in Human Mutation
- Vol. 30 (3) , 352-362
OncogenicHRASmutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome
Costello syndrome (CS) is a rare congenital disorder characterized by failure to thrive, craniofacial dysmorphisms, cardiac and skin abnormalities, mental retardation, and predisposition to malignancies. CS is caused by heterozygous gain-of-function mutations in HRAS that also occur as somatic alterations in human tumors. HRAS is one of the three classical RAS proteins and cycles between an active, GTP- and an inactive, GDP-bound conformation. We used primary human skin fibroblasts from patients with CS as a model system to study the functional consequences of HRAS mutations on endogenous signaling pathways. The GTP-bound form of HRAS was significantly enriched in CS compared with normal fibroblasts. Active HRAS is known to stimulate both the RAF-MEK-ERK and the PI3K–AKT signaling cascade. Phosphorylation of MEK and ERK was normal in CS fibroblasts under basal conditions and slightly prolonged after epidermal growth factor (EGF) stimulation. Interestingly, basal phosphorylation of AKT was increased yet more in CS fibroblasts. Moreover, AKT phosphorylation was diminished in the early and enhanced in the late phase of EGF stimulation. Taken together, these results document that CS-associated HRAS mutations result in prolonged signal flux in a ligand-dependent manner. Our data suggest that altered cellular response to growth factors rather than constitutive activation of HRAS downstream signaling molecules may contribute to some of the clinical features in patients with CS. Hum Mutat 0,1–11, 2008.
- 24 February 2009
- Published by Hindawi Limited in Human Mutation
- Vol. 30 (3) , 352-362
OncogenicHRASmutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome
Costello syndrome (CS) is a rare congenital disorder characterized by failure to thrive, craniofacial dysmorphisms, cardiac and skin abnormalities, mental retardation, and predisposition to malignancies. CS is caused by heterozygous gain-of-function mutations in HRAS that also occur as somatic alterations in human tumors. HRAS is one of the three classical RAS proteins and cycles between an active, GTP- and an inactive, GDP-bound conformation. We used primary human skin fibroblasts from patients with CS as a model system to study the functional consequences of HRAS mutations on endogenous signaling pathways. The GTP-bound form of HRAS was significantly enriched in CS compared with normal fibroblasts. Active HRAS is known to stimulate both the RAF-MEK-ERK and the PI3K–AKT signaling cascade. Phosphorylation of MEK and ERK was normal in CS fibroblasts under basal conditions and slightly prolonged after epidermal growth factor (EGF) stimulation. Interestingly, basal phosphorylation of AKT was increased yet more in CS fibroblasts. Moreover, AKT phosphorylation was diminished in the early and enhanced in the late phase of EGF stimulation. Taken together, these results document that CS-associated HRAS mutations result in prolonged signal flux in a ligand-dependent manner. Our data suggest that altered cellular response to growth factors rather than constitutive activation of HRAS downstream signaling molecules may contribute to some of the clinical features in patients with CS. Hum Mutat 0,1–11, 2008.
- 1 July 2008
- Published by Wolters Kluwer Health in Clinical Dysmorphology
- Vol. 17 (3) , 181-185
No mutation in genes of the WNT signaling pathway in patients with Zimmermann–Laband syndrome
- 1 July 2008
- Published by Wolters Kluwer Health in Clinical Dysmorphology
- Vol. 17 (3) , 181-185
No mutation in genes of the WNT signaling pathway in patients with Zimmermann–Laband syndrome
- 27 November 2007
- Published by Wiley in Clinical Genetics
- Vol. 73 (1) , 62-70
Mutation and phenotypic spectrum in patients with cardio‐facio‐cutaneous and Costello syndrome
Cardio‐facio‐cutaneous (CFC) and Costello syndrome (CS) are congenital disorders with a significant clinical overlap. The recent discovery of heterozygous mutations in genes encoding components of the RAS–RAF–MAPK pathway in both CFC and CS suggested a similar underlying pathogenesis of these two disorders. While CFC is heterogeneous with mutations in BRAF, MAP2K1, MAP2K2 and KRAS, HRAS alterations are almost exclusively associated with CS. We carried out a comprehensive mutation analysis in 51 CFC‐affected patients and 31 individuals with CS. Twelve different BRAF alterations were found in twenty‐four patients with CFC (47.0%), two MAP2K1 mutations in five (9.8%) and two MAP2K2 sequence variations in three CFC‐affected individuals (5.9%), whereas three patients had a KRAS alteration (5.9%). We identified four different missense mutations of HRAS in twenty‐eight cases with CS (90.3%), while KRAS mutations were detected in two infants with a phenotype meeting criteria for CS (6.5%). In 14 informative families, we traced the parental origin of HRAS alterations and demonstrated inheritance of the mutated allele exclusively from the father, further confirming a paternal bias in the parental origin of HRAS mutations in CS. Careful clinical evaluation of patients with BRAF and MAP2K1/2 alterations revealed the presence of slight phenotypic differences regarding craniofacial features in MAP2K1‐ and MAP2K2‐mutation positive individuals, suggesting possible genotype–phenotype correlations.
- 27 November 2007
- Published by Wiley in Clinical Genetics
- Vol. 73 (1) , 62-70
Mutation and phenotypic spectrum in patients with cardio‐facio‐cutaneous and Costello syndrome
Cardio‐facio‐cutaneous (CFC) and Costello syndrome (CS) are congenital disorders with a significant clinical overlap. The recent discovery of heterozygous mutations in genes encoding components of the RAS–RAF–MAPK pathway in both CFC and CS suggested a similar underlying pathogenesis of these two disorders. While CFC is heterogeneous with mutations in BRAF, MAP2K1, MAP2K2 and KRAS, HRAS alterations are almost exclusively associated with CS. We carried out a comprehensive mutation analysis in 51 CFC‐affected patients and 31 individuals with CS. Twelve different BRAF alterations were found in twenty‐four patients with CFC (47.0%), two MAP2K1 mutations in five (9.8%) and two MAP2K2 sequence variations in three CFC‐affected individuals (5.9%), whereas three patients had a KRAS alteration (5.9%). We identified four different missense mutations of HRAS in twenty‐eight cases with CS (90.3%), while KRAS mutations were detected in two infants with a phenotype meeting criteria for CS (6.5%). In 14 informative families, we traced the parental origin of HRAS alterations and demonstrated inheritance of the mutated allele exclusively from the father, further confirming a paternal bias in the parental origin of HRAS mutations in CS. Careful clinical evaluation of patients with BRAF and MAP2K1/2 alterations revealed the presence of slight phenotypic differences regarding craniofacial features in MAP2K1‐ and MAP2K2‐mutation positive individuals, suggesting possible genotype–phenotype correlations.
- 1 December 2006
- Published by Georg Thieme Verlag KG in Neuropediatrics
- Vol. 37 (06) , P105
Elevated urine catecholamine metabolites: Indicating parameters for identification of Costello syndrome
Elevated urine catecholamine metabolites are well known indicators for pheochromocytomas and neuroblastomas with associated myoclonus opsoclonus syndrome. We report on a 3 months old child patient of unrelated parents with failure to thrive since the first weeks of life, hyperhidrosis, tachycardia without variability of frequency and tachydyspnoea. Furtheron a cardiomyopathy developed. We suspected a disturbance in the sympathic nervous system regulation and performed an analysis of urine catecholamine metabolites which showed a concentration of vanillylmandelic acid within the upper level of the normal range. MIBG scintigraphy did not show any signs of an expected pheochromocytoma. Regarding to associated distinctive facial abnormalities, lax skin, especially in the region of hands and feet, and persistent growth retardation we suspected a Costello syndrome. The 1987 described Costello syndrome is a rare congenital malformation syndrome. It is caused by recently discovered mutations in the HRAS gene. Until now only de novo mutations are known. Clinically the Costello syndrome consists of distinctive facial, skin and musculosceletal features, the above mentioned autonomic symptoms with development of a cardiomyopathy, furthermore cardiac dysrhythmias, postnatal growth retardation and psychomotor developmental delay. Predisposition for tumor development especially rhabdomyosarcomas is described. The symptoms will usually improve with ongoing age. Therapy of the Costello syndrome consists of symptomatical procedures. Tube feeding by gastrostomy is nearly almost mandatory. A tracheostomy could be able to improve ventilation problems in case of severe tracheal and laryngeal malacia. In our patient we found a de novo heterozygous missense mutation c.34G→A in exon 2 of the HRAS gene. Nutrition is secured by gastrostomy tube feeding. There still exist recurrent gastrointestinal problems with vomiting, diarrhoea and meteorism. The cardiac situation could be improved dramatically by beta blocker therapy.
- 1 December 2006
- Published by Georg Thieme Verlag KG in Neuropediatrics
- Vol. 37 (06) , P105
Elevated urine catecholamine metabolites: Indicating parameters for identification of Costello syndrome
Elevated urine catecholamine metabolites are well known indicators for pheochromocytomas and neuroblastomas with associated myoclonus opsoclonus syndrome. We report on a 3 months old child patient of unrelated parents with failure to thrive since the first weeks of life, hyperhidrosis, tachycardia without variability of frequency and tachydyspnoea. Furtheron a cardiomyopathy developed. We suspected a disturbance in the sympathic nervous system regulation and performed an analysis of urine catecholamine metabolites which showed a concentration of vanillylmandelic acid within the upper level of the normal range. MIBG scintigraphy did not show any signs of an expected pheochromocytoma. Regarding to associated distinctive facial abnormalities, lax skin, especially in the region of hands and feet, and persistent growth retardation we suspected a Costello syndrome. The 1987 described Costello syndrome is a rare congenital malformation syndrome. It is caused by recently discovered mutations in the HRAS gene. Until now only de novo mutations are known. Clinically the Costello syndrome consists of distinctive facial, skin and musculosceletal features, the above mentioned autonomic symptoms with development of a cardiomyopathy, furthermore cardiac dysrhythmias, postnatal growth retardation and psychomotor developmental delay. Predisposition for tumor development especially rhabdomyosarcomas is described. The symptoms will usually improve with ongoing age. Therapy of the Costello syndrome consists of symptomatical procedures. Tube feeding by gastrostomy is nearly almost mandatory. A tracheostomy could be able to improve ventilation problems in case of severe tracheal and laryngeal malacia. In our patient we found a de novo heterozygous missense mutation c.34G→A in exon 2 of the HRAS gene. Nutrition is secured by gastrostomy tube feeding. There still exist recurrent gastrointestinal problems with vomiting, diarrhoea and meteorism. The cardiac situation could be improved dramatically by beta blocker therapy.
- 1 November 2006
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 79 (5) , 878-889
Mutations of the Mitochondrial Holocytochrome c–Type Synthase in X-Linked Dominant Microphthalmia with Linear Skin Defects Syndrome
- 1 November 2006
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 79 (5) , 878-889
Mutations of the Mitochondrial Holocytochrome c–Type Synthase in X-Linked Dominant Microphthalmia with Linear Skin Defects Syndrome
- 1 October 2005
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 125 (4) , 700-704
Disruption of ERBB2IP Is not Associated with Dystrophic Epidermolysis Bullosa in Both Father and Son Carrying a Balanced 5;13 Translocation
- 1 October 2005
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 125 (4) , 700-704
Disruption of ERBB2IP Is not Associated with Dystrophic Epidermolysis Bullosa in Both Father and Son Carrying a Balanced 5;13 Translocation
- Open Access
- 1 February 2005
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 280 (8) , 6879-6889
αPIX Associates with Calpain 4, the Small Subunit of Calpain, and Has a Dual Role in Integrin-mediated Cell Spreading
- 1 February 2005
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 280 (8) , 6879-6889
Open AccessαPIX Associates with Calpain 4, the Small Subunit of Calpain, and Has a Dual Role in Integrin-mediated Cell Spreading
- Open Access
- 15 January 2003
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 12 (2) , 155-167
Interaction of alphaPIX (ARHGEF6) with beta-parvin (PARVB) suggests an involvement of alphaPIX in integrin-mediated signaling
Members of the Rho GTPase family are key regulatory molecules that link surface receptors to the organization of the actin cytoskeleton. It is now well established that these small GTPases are also crucial for neuronal morphogenesis and connectivity. Moreover, mutations in ARHGEF6 (also known as αPIX or Cool-2 ), encoding a Rac1/Cdc42-specific guanine nucleotide exchange factor, have been implicated in X-linked mental retardation. In an attempt to get insight into the biological function of ARHGEF6 and the upstream signaling cascades leading to its activation, we used the full-length coding region of ARHGEF6 as bait in yeast-two hybrid screens and identified PARVB (β-parvin or affixin) as a novel binding partner. The interaction was confirmed by co-immunoprecipitation and GST pull-down. We showed by immunofluorescence that ARHGEF6 and PARVB co-localize at the cell periphery to lamellipodia and ruffles in well-spread and actively spreading cells adhered to fibronectin. In addition, interaction of ARHGEF6 to ARHGEF7 (βPIX or Cool-1), a close homolog of ARHGEF6, was confirmed. In in vivo assays, two ARHGEF6 mutations identified previously in patients with X-linked non-specific mental retardation, ARHGEF6 δaa56–83 and δaa396–776, abolished interaction of ARHGEF6 to PARVB. Binding between ARHGEF6 and ARHGEF7 was not affected by ARHGEF6 δaa56–83 but did not occur with ARHGEF6 δaa396–776. These data suggest that both the N-terminal calponin homology (CH) and C-terminal coiled-coil domains are necessary for the ARHGEF6-PARVB binding. In contrast, it seems that only the coiled-coil domain is required for the interaction and heterodimerization of ARHGEF6 and ARHGEF7. PARVB is known to interact with integrin-linked kinase (ILK) and is involved in the early stage of cell–substrate interaction through integrins. The identification of PARVB as an ARHGEF6 interacting partner together with the co-localization of ARHGEF6 and ILK in spreading cells suggest that ARHGEF6 is involved in integrin-mediated signaling leading to activation of the GTPases Rac1 and/or Cdc42.
- 15 January 2003
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 12 (2) , 155-167
Open AccessInteraction of alphaPIX (ARHGEF6) with beta-parvin (PARVB) suggests an involvement of alphaPIX in integrin-mediated signaling
Members of the Rho GTPase family are key regulatory molecules that link surface receptors to the organization of the actin cytoskeleton. It is now well established that these small GTPases are also crucial for neuronal morphogenesis and connectivity. Moreover, mutations in ARHGEF6 (also known as αPIX or Cool-2 ), encoding a Rac1/Cdc42-specific guanine nucleotide exchange factor, have been implicated in X-linked mental retardation. In an attempt to get insight into the biological function of ARHGEF6 and the upstream signaling cascades leading to its activation, we used the full-length coding region of ARHGEF6 as bait in yeast-two hybrid screens and identified PARVB (β-parvin or affixin) as a novel binding partner. The interaction was confirmed by co-immunoprecipitation and GST pull-down. We showed by immunofluorescence that ARHGEF6 and PARVB co-localize at the cell periphery to lamellipodia and ruffles in well-spread and actively spreading cells adhered to fibronectin. In addition, interaction of ARHGEF6 to ARHGEF7 (βPIX or Cool-1), a close homolog of ARHGEF6, was confirmed. In in vivo assays, two ARHGEF6 mutations identified previously in patients with X-linked non-specific mental retardation, ARHGEF6 δaa56–83 and δaa396–776, abolished interaction of ARHGEF6 to PARVB. Binding between ARHGEF6 and ARHGEF7 was not affected by ARHGEF6 δaa56–83 but did not occur with ARHGEF6 δaa396–776. These data suggest that both the N-terminal calponin homology (CH) and C-terminal coiled-coil domains are necessary for the ARHGEF6-PARVB binding. In contrast, it seems that only the coiled-coil domain is required for the interaction and heterodimerization of ARHGEF6 and ARHGEF7. PARVB is known to interact with integrin-linked kinase (ILK) and is involved in the early stage of cell–substrate interaction through integrins. The identification of PARVB as an ARHGEF6 interacting partner together with the co-localization of ARHGEF6 and ILK in spreading cells suggest that ARHGEF6 is involved in integrin-mediated signaling leading to activation of the GTPases Rac1 and/or Cdc42.